Invitae, Alnylam to Provide Free Genetic Testing for Primary Hyperoxaluria

Oct 29, 2018

NEW YORK (GenomeWeb) — Invitae announced today that it is partnering with RNAi therapeutics firm Alnylam Pharmaceuticals to provide free genetic testing to improve diagnosis and management of a rare inherited disorder called primary hyperoxaluria.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Breaking News

Mar

27

Featured Webinar

How One NGS Core Lab Reduced Sequencing Costs with a Novel Library Normalization Kit

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost.

Apr

09

Featured Webinar

Combining AI with Community-Driven Insights: Advanced Diagnosis of Inherited Cardiac Diseases

This webinar will present the utility of a personalized in silico analytical approach for the routine clinical diagnosis of channelopathies and cardiomyopathies.

Apr

11

Featured Webinar

The 'Dark Matter' of Cancer Genomics: Revealing Undetected Structural Variants in Leukemia

This webinar will review a recent study that applied whole-genome sequencing and optical genome mapping to identify a large number of previously undetected somatic structural variants in leukemia samples.

Apr

30

Featured Webinar

Novel Methods for Improving De Novo Transcriptome Annotation with Long-Read Transcript Sequencing

This webinar will discuss novel long-read transcript sequencing (LRTseq) methods for transcriptome annotation that could increase the efficiency and accuracy of future sequencing projects.

Menu